My Fulbright research aims to examine and develop synthetic mRNA vaccines in agriculture and biosecurity. COVID-19 demonstrated the effectiveness of mRNA vaccines. Novel mRNA vaccine designs are readily iterated, rapid, scalable, and are cost-effective to produce, rendering them ideal tools for the challenges of managing infectious diseases globally.
Garry is the Director of the Australian Institute for Microbiology & Infection (AIMI) at UTS. Following his PhD at the University of Sydney, he did postdoctoral training at The Institute for Genome Research (TIGR) in Rockville, Maryland, working on microbial genomics and pathogenesis, and joined the Faculty there in 2005. In 2007, Garry co-founded the Institute for Genome Sciences (IGS) at the University of Maryland School of Medicine. In 2014, he was recruited to the University of Technology Sydney and became AIMI Director in 2019. Garry also founded and led the Vaccine & RNA Design Centre (VRDC), underpinning his Fulbright vaccine design project.
Garry’s Fulbright research aims to examine and develop synthetic mRNA vaccines in agriculture and biosecurity.